source
- Natera partners with Angiex to evaluate Signatera blood test in AGX101 cancer trialNatera announced a collaboration with biotech Angiex to assess its Signatera circulating tumor DNA blood test in the context of Angiex’s early‑stage clinical trial of AGX101. Angiex, based in Camb…
- Industry and patient groups urge FDA to revise master protocol guidanceIndustry groups and patient advocacy organizations have written to the U.S. Food and Drug Administration asking for several revisions to its recently updated draft guidance on master protocols for…